Publicacións (71) Publicacións de PEDRO PABLO MEDINA VICO

2024

  1. Activation-induced cytidine deaminase causes recurrent splicing mutations in diffuse large B-cell lymphoma

    Molecular Cancer

2023

  1. Author Correction: Tumour mutations in long noncoding RNAs enhance cell fitness (Nature Communications, (2023), 14, 1, (3342), 10.1038/s41467-023-39160-7)

    Nature Communications

  2. BCL7A is silenced by hypermethylation to promote acute myeloid leukemia

    Biomarker Research, Vol. 11, Núm. 1

  3. Clinical applications of DNA methylation profiling in lung cancer

    Translational Lung Cancer Research

  4. Defining the first bona fide cell model for SMARCA4-deficient, undifferentiated tumor

    Journal of Pathology, Vol. 261, Núm. 1, pp. 5-10

  5. Recurrent splice site mutations affect key diffuse large B-cell lymphonma genes

    Memorias académicas de La Real Academia de Medicina y Cirugía de Sevilla: año 2023 (Real Academia de Medicina y Cirugía de Sevilla), pp. 315-317

  6. SWI/SNF complexes in hematological malignancies: biological implications and therapeutic opportunities

    Molecular Cancer, Vol. 22, Núm. 1

  7. Valor terapéutico de la restauración de microARNs supresores tumorales en el desarrollo de cáncer de pulmón

    Anales de la Real Academia Nacional de Farmacia, Vol. 89, Núm. 3, pp. 287-296

2022

  1. Acceleration of the DNA methylation clock among lynch syndrome-associated mutation carriers

    BMC medical genomics, Vol. 15, Núm. 1, pp. 45

  2. EZH2 endorses cell plasticity to non-small cell lung cancer cells facilitating mesenchymal to epithelial transition and tumour colonization

    Oncogene, Vol. 41, Núm. 28, pp. 3611-3624

  3. Los ARN no codificantes como biomarcadoresen la leucemia linfoblástica aguda de células B pediátrica

    Memorias académicas de la Real Academia de Medicina y Cirugía de Sevilla: año 2022 (Real Academia de Medicina y Cirugía de Sevilla), pp. 330-331

  4. Multi-hallmark long noncoding RNA maps reveal non-small cell lung cancer vulnerabilities

    Cell Genomics, Vol. 2, Núm. 9

  5. Multi-omic alterations of the SWI/SNF complex define a clinical subgroup in lung adenocarcinoma

    Clinical Epigenetics, Vol. 14, Núm. 1

  6. Oncomicroarns y sus futuras aplicaciones farmacoloìgicas

    Anales de la Real Academia Nacional de Farmacia, Vol. 88, Núm. 1, pp. 7-18

  7. Opportunities of miRNAs in cancer therapeutics

    MicroRNA in Human Malignancies (Elsevier), pp. 153-164

  8. PKP1 and MYC create a feedforward loop linking transcription and translation in squamous cell lung cancer

    Cellular Oncology, Vol. 45, Núm. 2, pp. 323-332

  9. Recurrent splice site mutations affect key diffuse large B-cell lymphoma genes

    Blood

2021

  1. Genome-wide CRISPR interference screen identifies long non-coding RNA loci required for differentiation and pluripotency

    PLoS ONE, Vol. 16, Núm. 11 November

  2. SMARCA4 deficient tumours are vulnerable to KDM6A/UTX and KDM6B/JMJD3 blockade

    Nature Communications, Vol. 12, Núm. 1

  3. The SWI/SNF complex regulates the expression of miR-222, a tumor suppressor microRNA in lung adenocarcinoma

    Human Molecular Genetics, Vol. 30, Núm. 23, pp. 2263-2271